DK1387854T3 - SFRP og peptidmotiver som interagerer med SFRP og fremgangsmåder til anvendelse deraf - Google Patents

SFRP og peptidmotiver som interagerer med SFRP og fremgangsmåder til anvendelse deraf

Info

Publication number
DK1387854T3
DK1387854T3 DK02707454.1T DK02707454T DK1387854T3 DK 1387854 T3 DK1387854 T3 DK 1387854T3 DK 02707454 T DK02707454 T DK 02707454T DK 1387854 T3 DK1387854 T3 DK 1387854T3
Authority
DK
Denmark
Prior art keywords
sfrp
methods
interact
peptide motifs
motif
Prior art date
Application number
DK02707454.1T
Other languages
Danish (da)
English (en)
Inventor
Jeffrey S Rubin
Bernard Weisblum
Aykut Uren
Nicole Joy Horwood
Matthew Todd Gillespie
Brian K Kay
Original Assignee
Us Health
St Vincents Inst Med Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health, St Vincents Inst Med Res filed Critical Us Health
Application granted granted Critical
Publication of DK1387854T3 publication Critical patent/DK1387854T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0643—Osteoclasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
DK02707454.1T 2001-01-10 2002-01-10 SFRP og peptidmotiver som interagerer med SFRP og fremgangsmåder til anvendelse deraf DK1387854T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26090801P 2001-01-10 2001-01-10
PCT/US2002/000869 WO2002055547A2 (en) 2001-01-10 2002-01-10 Sfrp and peptide motifs that interact with sfrp and methods of their use

Publications (1)

Publication Number Publication Date
DK1387854T3 true DK1387854T3 (da) 2012-07-09

Family

ID=22991151

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02707454.1T DK1387854T3 (da) 2001-01-10 2002-01-10 SFRP og peptidmotiver som interagerer med SFRP og fremgangsmåder til anvendelse deraf

Country Status (11)

Country Link
US (2) US7488710B2 (enExample)
EP (1) EP1387854B1 (enExample)
JP (3) JP4029041B2 (enExample)
AT (1) ATE550345T1 (enExample)
AU (1) AU2002241859B2 (enExample)
CA (1) CA2434672C (enExample)
CY (1) CY1112875T1 (enExample)
DK (1) DK1387854T3 (enExample)
ES (1) ES2385666T3 (enExample)
PT (1) PT1387854E (enExample)
WO (1) WO2002055547A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1731908B1 (en) * 2004-03-31 2010-09-01 Kazuo Shinya Method of biosubstance trapping, structural analysis or/and identification with use of a labeling substance
KR20070102684A (ko) * 2004-12-23 2007-10-19 몰메드 에스피에이 접합 생성물
WO2008061029A1 (en) * 2006-11-10 2008-05-22 Wyeth Aryl sulfonamide derivatives and methods of their use
MX2010010266A (es) * 2008-03-21 2010-12-14 Adlyfe Inc Uso de pireno para llevar peptidos a traves de la barrera hematoencefalica.
NZ589539A (en) * 2008-05-16 2012-08-31 Bioexx Specialty Proteins Ltd Oilseed protein concentrates and isolates, and processes for the production thereof
JP2013006783A (ja) * 2011-06-22 2013-01-10 Nagasaki Univ 荷重感知遺伝子
FI3116521T3 (fi) * 2014-03-14 2024-10-30 Univ New York State Res Found Luun kasvun ja luun rappeutumisen neurogeeninen regulaatio
DK3139979T3 (da) 2014-05-07 2023-10-09 Boehringer Ingelheim Int Enhed, forstøver og fremgangsmåde
US12344886B2 (en) * 2017-06-15 2025-07-01 Technion Research & Development Foundation Limited Compositions and methods for detection of genomic variations
EP3696192A1 (en) * 2019-02-15 2020-08-19 Consejo Superior De Investigaciones Científicas Therapeutic target and monoclonal antibodies against it for the diagnosis and treatment of alzheimer´s disease

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5238839A (en) 1988-02-09 1993-08-24 Dana Farber Cancer Institute Nucleic Acids Encoding proteins which induce immunological effector cell activation and chemattraction, vectors, and recombinant cells
US5204328A (en) 1990-06-26 1993-04-20 Merck & Co., Inc. Peptides having atrial natriuretic factor activity
CA2117282A1 (en) 1991-11-22 1993-05-27 Ofer Lider Non-peptidic surrogates of the arg-gly-asp sequence and pharmaceutical compositions comprosing them
US5578569A (en) 1993-03-12 1996-11-26 Tam; Cherk S. Method of increasing bone growth
US5536814A (en) 1993-09-27 1996-07-16 La Jolla Cancer Research Foundation Integrin-binding peptides
US5726156A (en) 1995-03-06 1998-03-10 Trega Biosciences, Inc. Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels
US5846932A (en) 1993-11-12 1998-12-08 Genentech, Inc. Receptor specific atrial natriuretic peptides
US5632983A (en) 1994-11-17 1997-05-27 University Of South Florida Method for treating secondary immunodeficiency
US5861483A (en) 1996-04-03 1999-01-19 Pro-Neuron, Inc. Inhibitor of stem cell proliferation and uses thereof
WO1997039357A1 (en) 1996-04-12 1997-10-23 The Board Of Trustees Of The Leland Stanford Junior University Wnt RECEPTOR COMPOSITIONS AND METHODS
US5851984A (en) 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
PT932678E (pt) 1996-09-24 2006-07-31 Tanox Inc Familia de genes que codificam peptidos relacionados com apoptose, peptidos por eles codificados e metodos para sua utilizacao
US5939271A (en) 1997-02-19 1999-08-17 The Regents Of The University Of California Netrin receptor
BR9808545A (pt) 1997-04-16 2000-05-23 Amgen Inc ácido nucleico isolado, vetor de expressão, célula hospedeira, processos para produzir uma proteìna de ligação da osteoprotegerina, para detectar a presença de uma proteìna de ligação à osteoprotegerina em uma amostra biológica, para avaliar a capacidade de um composto candidato de ligar-se a uma proteìna de ligação da osteoprotegerina e de um composto de teste para aumentar ou reduzir a ligação da proteìna de ligação da osteoprotegerina a odar, para regular a expressão de uma proteìna de ligação da osteoprotegerina em um animal e para prevenir ou tratar de doença óssea em um mamìfero, polipeptìdeo, protéina de ligação da osteroprotegerina purificada e isolada, ou seu fragmento, análogo ou derivado, e, anticorpo ou seu fragmento
US6043053A (en) 1997-05-23 2000-03-28 Smithkline Beecham Corporation Wnt-3 polynucleotides
AU7704498A (en) 1997-05-29 1998-12-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Human frp and fragments thereof including methods for using them
EP1012262A4 (en) 1997-08-12 2002-11-06 Human Genome Sciences Inc HFLP PROTEIN HFLP
WO1999026960A2 (en) 1997-11-25 1999-06-03 Millennium Pharmaceuticals, Inc. Genes encoding frizzled-like proteins
WO1999029865A2 (en) 1997-12-12 1999-06-17 The Rockefeller University A protein belonging to the tnf superfamily, nucleic acids encoding same, and methods of use thereof
JPH11196864A (ja) 1998-01-08 1999-07-27 Deinabekku Kenkyusho:Kk 破骨細胞の分化を誘導する方法
US6110718A (en) * 1998-03-20 2000-08-29 Wayne State University Mammalian putative phosphatidylinositol-4-phosphate-5-kinase
WO2001057188A2 (en) 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
AU7131200A (en) 1999-09-13 2001-04-17 Wyeth Pharmaceutical compositions and methods of using secreted frizzled related protein
US6600018B1 (en) * 2000-04-10 2003-07-29 The United States Of America As Represented By The Department Of Health And Human Services Secreted frizzled related protein, sFRP, fragments and methods of use thereof
JP2002181893A (ja) * 2000-12-11 2002-06-26 Mitsubishi Electric Corp 半導体装置の検査方法および検査装置

Also Published As

Publication number Publication date
US7488710B2 (en) 2009-02-10
CY1112875T1 (el) 2016-04-13
US20040077828A1 (en) 2004-04-22
US8334260B2 (en) 2012-12-18
ES2385666T3 (es) 2012-07-30
JP4029041B2 (ja) 2008-01-09
CA2434672C (en) 2014-03-25
JP4248583B2 (ja) 2009-04-02
PT1387854E (pt) 2012-06-26
JP2009005704A (ja) 2009-01-15
JP2007300920A (ja) 2007-11-22
JP2005501508A (ja) 2005-01-20
WO2002055547A9 (en) 2002-10-31
JP4248600B2 (ja) 2009-04-02
WO2002055547A3 (en) 2003-11-20
AU2002241859B2 (en) 2007-07-19
WO2002055547A2 (en) 2002-07-18
EP1387854A2 (en) 2004-02-11
EP1387854B1 (en) 2012-03-21
US20080145884A1 (en) 2008-06-19
ATE550345T1 (de) 2012-04-15
CA2434672A1 (en) 2002-07-18

Similar Documents

Publication Publication Date Title
IL161016A (en) Polypeptides capable of ang-2 binding
CY1112875T1 (el) Sfrp και πεπτιδικα μοτιβα που διαντιδρουν με την sfrp και μεθοδοι χρησης τους
DK1645631T3 (da) Neisseria antigener og præparater
DK1149905T3 (da) Fremgangsmåder og præparat til polypeptidteknologi
NO960767L (no) Protocadherinproteiner og deres anvendelse
DE50112802D1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
BR0312521A (pt) Métodos para a separação e a purificação de fibrinogênio e de pelo menos uma outra proteìna e para a co-purificação de fibrinogênio e de fator xiii, uso de cromatografia de afinidade com ìon de metal imobilizado, fibrinogênio, kit farmacêutico, e, formulações farmacêutica e de fibrinogênio liofilizado
ATE363531T1 (de) Claudin polypeptide
GB0104588D0 (en) Novel p-53 inducible protein
DE60118935D1 (de) Dna & protein bindende miniatur proteine
EA200600042A1 (ru) Способы образования дисульфидных связей и гликозилирования белков и реагенты, применяемые в этих способах
SE9602822D0 (sv) New receptor
EA200400392A1 (ru) Связывающий каспазу-8 белок, его получение и применение
BR0315222A (pt) Promotor de il-18bp, sua preparação e uso
DE60211227D1 (de) Androgenrezeptor-Komplex assoziiertes Protein
DK2186898T3 (da) Blomstrings-induktion
DE60238243D1 (de) Polypeptide, abgeleitet von der amyloid vorläuferprotein (app), und ihre verwendungen
TW200635950A (en) Specific binding agents of human angiopoietin-2
BRPI0216042B8 (pt) polipeptídeo capaz de se ligar a ang-2, vetor de expressão, célula hospedeira, composição farmacêutica, e, uso dos referidos polipeptídeos.
EP1724347A3 (en) DNA & protein binding miniature proteins
AU2002356514A1 (en) Clasp membrane proteins